ArticleInternational journal of general medicine2023
Prognostic Significance of Preoperative Lactate Dehydrogenase to Albumin Ratio in Breast Cancer: A Retrospective Study.
Article in International journal of general medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- The value of LAR in predicting neoadjuvant therapy response and prognosis in HER2-positive breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Improved 28-day mortality prediction by combining Lactate Dehydrogenase-to-Albumin Ratio(LAR) to lactate-enhanced Sequential Organ Failure Assessment (SOFA) score in patients with sepsis: a derivation and validation study.BMC infectious diseases · 2026Article
- Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Lactate dehydrogenase/albumin ratio predicts progression of disease within 24 months (POD24) in advanced-stage extranodal natural killer/T cell lymphoma.Annals of hematology · 2026Article
- Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Neuroblastoma.Children (Basel, Switzerland) · 2026Article
- Serum lactate Dehydrogenase-to-Albumin ratio in upper tract urothelial carcinoma: A promising prognostic biomarker.BMC urology · 2025Article
- Article
- The prognostic value of lactate dehydrogenase/albumin ratio in extranodal natural killer/T cell lymphoma.BMC cancer · 2025Article
- Prognostic value of the lactate dehydrogenase to albumin ratio in cancer patients.Frontiers in nutrition · 2025Article
- Prognostic significance of the preoperative lactate dehydrogenase-to-albumin ratio in patients undergoing radical resection for hilar cholangiocarcinoma.Frontiers in medicine · 2025Article
- Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy.Frontiers in immunology · 2025Article
- LAR, FAR, and PLR as prognostic factors in high-grade urothelial carcinoma of the bladder after surgery.Frontiers in oncology · 2025Article
- Article
- Prognostic value of the lactate dehydrogenase-to-albumin ratio for predicting mortality in critically ill pediatric patients: a retrospective cohort study.Frontiers in pediatrics · 2025Article
- Establishment and validation of a 28-day mortality prediction model based on the lactate dehydrogenase/albumin ratio in patients with severe pneumonia.Frontiers in medicine · 2025Article
- Does the LDH/Albumin Ratio Bring Novelty? A Comparative Analysis with Inflammatory Indices and Combined Models in Adult-Onset Still's Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Predictive and Prognostic Value of Inflammatory and Nutritional Indexes in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.Medicina (Kaunas, Lithuania) · 2024Article
- Effect of Preoperative Serum Lactate Dehydrogenase-to-Albumin Ratio on the Survival of Oral Cancer: A Retrospective Study.Journal of inflammation research · 2024Article
- Article
- Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Breast Cancer.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We explored the relationship between platelet count to lymphocyte count ratio (PLR), monocyte count to lymphocyte count ratio (MLR), lactate dehydrogenase to albumin ratio (LAR), and long-term survival in patients with breast cancer. Patients and Methods: We retrospectively analyzed the clinical and follow-up data of 134 patients with breast cancer. The receiver operating characteristic curve (ROC curve) was used to distinguish between the low and high ratio groups. The chi-square test or Fisher's exact test was used to calculate the differences among the investigation factors. The Kaplan-Meier method was used to draw the survival curves. Log rank test was used for univariate analysis, and Cox proportional hazards regression model was used for multivariate analysis. A P value of <0.05 was considered statistically significant. Results: The median follow-up time was 45 months. The PFS rates in the low group (LAR≤3.4066) at 18 months, 24 months, and 36 months were 100%, 100%, and 97.6%, and those in the high group (LAR > 3.4066) were 97.7%, 94.3%, and 87.3%, respectively. LAR was associated with Age (P=0.002) and BMI (body mass index) (P=0.002). Univariate analysis showed that Tumor size (P=0.027), Node positivity (P<0.001), TNM (tumor-node-metastasis) stage (P<0.001), PLR (P=0.034), MLR (P=0.038), and LAR (P=0.035) were significantly associated with PFS (progression-free survival) in breast cancer patients. Multivariate analysis showed that Node positivity (P<0.001) and LAR (P=0.035) were associated with PFS, while PLR and MLR were not independent prognostic indicators. Conclusion: Preoperative high LAR will be an independent predictor of prognosis in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.